AIM: Clinical studies have shown that statin use may modify the risk of kidney cancer. However, these studies yielded different results. To quantify the association between statin use and risk of kidney cancer, we performed a detailed meta-analysis of published studies regarding this subject. METHODS: A literature search was carried out using MEDLINE, EMBASE and the Cochrane database between January 1966 and October 2012. Prior to performing a meta-analysis, the studies were evaluated for publication bias and heterogeneity. Fixed effect and random effect models were used to estimate summary relative risks (RR) and the corresponding 95% confidence intervals (CIs). Subgroup analyses and sensitivity analysis were also performed. RESULTS: A total of 12 (two randomized controlled trials, five cohort, and five case-control) studies contributed to the analysis. There was heterogeneity among the studies but no evidence of publication bias. Pooled results indicated a non-significant decrease of total kidney cancer risk among all statin users (RR = 0.92, 95% CI 0.71, 1.19). Long term statin use did not significantly affect the risk of total kidney cancer (RR = 1.01, 95% CI 0.83, 1.22). In our subgroup analyses, the results were not substantially affected by study design, confounder adjustment and gender. Furthermore, sensitivity analysis confirmed the stability of the results. CONCLUSION: The findings of this meta-analysis suggested that there was no association between statin use and risk of kidney cancer. More studies, especially randomized controlled trials and high quality cohort studies with larger sample size and well controlled confounding factors, are needed to confirm this association in the future.
AIM: Clinical studies have shown that statin use may modify the risk of kidney cancer. However, these studies yielded different results. To quantify the association between statin use and risk of kidney cancer, we performed a detailed meta-analysis of published studies regarding this subject. METHODS: A literature search was carried out using MEDLINE, EMBASE and the Cochrane database between January 1966 and October 2012. Prior to performing a meta-analysis, the studies were evaluated for publication bias and heterogeneity. Fixed effect and random effect models were used to estimate summary relative risks (RR) and the corresponding 95% confidence intervals (CIs). Subgroup analyses and sensitivity analysis were also performed. RESULTS: A total of 12 (two randomized controlled trials, five cohort, and five case-control) studies contributed to the analysis. There was heterogeneity among the studies but no evidence of publication bias. Pooled results indicated a non-significant decrease of total kidney cancer risk among all statin users (RR = 0.92, 95% CI 0.71, 1.19). Long term statin use did not significantly affect the risk of total kidney cancer (RR = 1.01, 95% CI 0.83, 1.22). In our subgroup analyses, the results were not substantially affected by study design, confounder adjustment and gender. Furthermore, sensitivity analysis confirmed the stability of the results. CONCLUSION: The findings of this meta-analysis suggested that there was no association between statin use and risk of kidney cancer. More studies, especially randomized controlled trials and high quality cohort studies with larger sample size and well controlled confounding factors, are needed to confirm this association in the future.
Authors: Karin Mausner-Fainberg; Galia Luboshits; Adi Mor; Sophia Maysel-Auslender; Ardon Rubinstein; Gad Keren; Jacob George Journal: Atherosclerosis Date: 2007-09-10 Impact factor: 5.162
Authors: Gary D Friedman; E Dawn Flick; Natalia Udaltsova; James Chan; Charles P Quesenberry; Laurel A Habel Journal: Pharmacoepidemiol Drug Saf Date: 2008-01 Impact factor: 2.890
Authors: Roger J Bedimo; Lesley S Park; Fatima M Shebl; Keith Sigel; Christopher T Rentsch; Kristina Crothers; Maria C Rodriguez-Barradas; Matthew Bidwell Goetz; Adeel A Butt; Sheldon T Brown; Cynthia Gibert; Amy C Justice; Janet P Tate Journal: AIDS Date: 2021-02-02 Impact factor: 4.632
Authors: Elena Arrigoni; Marzia Del Re; Leonardo Fidilio; Stefano Fogli; Romano Danesi; Antonello Di Paolo Journal: Int J Mol Sci Date: 2017-01-06 Impact factor: 5.923
Authors: Gwang Hun Jeong; Keum Hwa Lee; Jong Yeob Kim; Michael Eisenhut; Andreas Kronbichler; Hans J van der Vliet; Sung Hwi Hong; Jae Il Shin; Gabriele Gamerith Journal: J Clin Med Date: 2019-06-08 Impact factor: 4.241